JP2005510251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510251A5 JP2005510251A5 JP2003547966A JP2003547966A JP2005510251A5 JP 2005510251 A5 JP2005510251 A5 JP 2005510251A5 JP 2003547966 A JP2003547966 A JP 2003547966A JP 2003547966 A JP2003547966 A JP 2003547966A JP 2005510251 A5 JP2005510251 A5 JP 2005510251A5
- Authority
- JP
- Japan
- Prior art keywords
- sarcoidosis
- subject
- gene
- expression level
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 111
- 230000014509 gene expression Effects 0.000 claims description 91
- 201000000306 sarcoidosis Diseases 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
- 239000012472 biological sample Substances 0.000 claims description 50
- 108020004999 messenger RNA Proteins 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 18
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000000636 Northern blotting Methods 0.000 claims description 8
- 238000011529 RT qPCR Methods 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 8
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 5
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims 7
- 238000001262 western blot Methods 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000002493 microarray Methods 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 210000002726 cyst fluid Anatomy 0.000 claims 3
- 210000002751 lymph Anatomy 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 208000024794 sputum Diseases 0.000 claims 3
- 210000003802 sputum Anatomy 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 102000005228 Cyclic AMP Response Element Modulator Human genes 0.000 claims 2
- 108010056281 Cyclic AMP Response Element Modulator Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108010092574 CD69 antigen Proteins 0.000 claims 1
- 101150028299 CD69 gene Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 101710082744 T-cell receptor alpha chain C region Proteins 0.000 claims 1
- 102000005747 Transcription Factor RelA Human genes 0.000 claims 1
- 108010031154 Transcription Factor RelA Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 102000052620 human IL10 Human genes 0.000 claims 1
- 102000047410 human NFKB1 Human genes 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- -1 small molecule compound Chemical class 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 206010020094 Hilar lymphadenopathy Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33426401P | 2001-11-29 | 2001-11-29 | |
| PCT/EP2002/013448 WO2003046578A2 (en) | 2001-11-29 | 2002-11-28 | Method for the assessment and prognosis of sarcoidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510251A JP2005510251A (ja) | 2005-04-21 |
| JP2005510251A5 true JP2005510251A5 (enExample) | 2006-01-19 |
Family
ID=23306395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547966A Pending JP2005510251A (ja) | 2001-11-29 | 2002-11-28 | サルコイドーシスの評価法と予後判定法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050032062A1 (enExample) |
| EP (1) | EP1454145A2 (enExample) |
| JP (1) | JP2005510251A (enExample) |
| AU (1) | AU2002364277A1 (enExample) |
| WO (1) | WO2003046578A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ547877A (en) * | 2003-12-05 | 2009-07-31 | Bioinvent Int Ab | Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof |
| WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
| JP4512828B2 (ja) * | 2005-04-12 | 2010-07-28 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| WO2010151599A1 (en) * | 2009-06-23 | 2010-12-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Human leukocyte antigen alleles associated with advanced lung diseases |
| US20110111437A1 (en) * | 2009-10-08 | 2011-05-12 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomarkers For Prognosis of Pulmonary Diseases |
| JP5120570B2 (ja) * | 2010-02-15 | 2013-01-16 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| JP5574348B2 (ja) * | 2012-05-31 | 2014-08-20 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| US10781489B2 (en) | 2015-03-04 | 2020-09-22 | Wayne State University | Systems and methods to diagnose sarcoidosis and identify markers of the condition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014067A1 (en) * | 1992-12-14 | 1994-06-23 | T Cell Sciences, Inc. | Diagnosis and therapy of sarcoidosis |
-
2002
- 2002-11-28 WO PCT/EP2002/013448 patent/WO2003046578A2/en not_active Ceased
- 2002-11-28 JP JP2003547966A patent/JP2005510251A/ja active Pending
- 2002-11-28 AU AU2002364277A patent/AU2002364277A1/en not_active Abandoned
- 2002-11-28 US US10/497,349 patent/US20050032062A1/en not_active Abandoned
- 2002-11-28 EP EP02799048A patent/EP1454145A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510251A5 (enExample) | ||
| JP6430560B2 (ja) | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ | |
| JP2005520479A (ja) | 乾癬の確認、評価、予防および治療のための組成物、キットおよび方法 | |
| KR20110057188A (ko) | 바이오마커 프로파일 측정 시스템 및 방법 | |
| KR20160117606A (ko) | 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험 | |
| JPWO2003014395A1 (ja) | 気管支喘息の検査方法 | |
| JP2005510251A (ja) | サルコイドーシスの評価法と予後判定法 | |
| WO2021228125A1 (en) | Protein markers for assessing alzheimer's disease | |
| US20230083393A1 (en) | Multiple biomarkers for diagnosing lung cancer and use thereof | |
| JPWO2002052006A1 (ja) | アレルギー性疾患検査方法 | |
| Noh et al. | MAP17 is associated with the T‐helper cell cytokine‐induced down‐regulation of filaggrin transcription in human keratinocytes | |
| JP2004533830A (ja) | 慢性炎症性関節疾患のための診断、分子決定、及び治療開発のためのツール | |
| JP2012050369A (ja) | ＩｇＧ４関連疾患診断用マーカー及びその利用 | |
| CN118667940A (zh) | Ifp35和/或nmi在诊治银屑病中的应用 | |
| KR20250044214A (ko) | Covid-19 중증도 예측 및 경과 모니터링 방법 | |
| Butbul Aviel et al. | A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity | |
| US6962776B2 (en) | Methods and materials for evaluating cardiovascular conditions | |
| CN115873936B (zh) | 生物标志物cxcl8及其应用 | |
| JP7083757B2 (ja) | ドライアイ疾患の予後のための遺伝子シグネチャー | |
| KR20240136713A (ko) | 유방암의 골전이 예측 또는 진단용 조성물 및 이를 포함하는 키트 | |
| Al-Saffar et al. | Study the association of IRAK1 gene polymorphism and some immunological markers with the risk of rheumatoid arthritis incidence in sample of Iraqi patients | |
| CN110499366B (zh) | Pi15作为骨关节炎标志物的应用 | |
| JP2022516117A (ja) | ヘリコバクターピロリ連関疾患に対する遺伝子マーカー | |
| US20040058351A1 (en) | Method of examining for allergic disease | |
| JP7514458B2 (ja) | 関節リウマチ治療薬の奏効を予測する方法及びそれに用いるバイオマーカー |